Essential Insights
-
Researchers have developed an AI tool that accelerates the identification of genes linked to neurodevelopmental disorders like autism, epilepsy, and developmental delay, enhancing molecular diagnosis and targeted therapies.
-
Traditional gene discovery methods often miss genetic diagnoses for many patients; this AI approach complements those methods by predicting additional relevant genes based on existing data.
-
The AI models utilized single-cell gene expression data and incorporated over 300 biological features, resulting in significantly higher predictive accuracy for identifying neurodevelopmental disorder risk genes.
- The researchers aim for their models to validate emerging genes from sequencing studies, potentially speeding up gene discovery and improving patient diagnoses in neurodevelopmental conditions.
AI Boosts Discovery of Genes Linked to Neurodevelopmental Disorders
Researchers have developed an artificial intelligence (AI) approach that speeds up the identification of genes related to neurodevelopmental conditions such as autism spectrum disorder, epilepsy, and developmental delay. This innovative computational tool could revolutionize how scientists understand these disorders. It paves the way for accurate molecular diagnoses, helps clarify disease mechanisms, and aids in the development of targeted therapies. The study was published in the American Journal of Human Genetics.
Dr. Ryan S. Dhindsa, an assistant professor at Baylor College of Medicine, noted, "Although researchers have made major strides identifying different genes associated with neurodevelopmental disorders, many patients still do not receive a genetic diagnosis. This indicates that many more genes await discovery."
Typically, researchers sequence genomes of affected individuals and compare them with those without the disorders. However, Dhindsa and his team used a different approach. They applied AI to analyze patterns among genes already known to be linked to neurodevelopmental diseases. Then, they predicted additional genes that might also play a role in these conditions.
The researchers focused on gene expression data collected at the single-cell level from the developing human brain. Dhindsa pointed out, "We found that AI models trained solely on this expression data can robustly predict genes implicated in autism spectrum disorder, developmental delay, and epilepsy. But we wanted to take this work a step further."
To enhance their models, the team incorporated more than 300 additional biological features. These included measures of how tolerant genes are to mutations, their interactions with other known disease-associated genes, and their functions within various biological pathways.
"These models have exceptionally high predictive value," Dhindsa stated. "Top-ranked genes were up to six-fold more enriched for high-confidence neurodevelopmental disorder risk genes compared to metrics alone. Some top-ranking genes proved to be 45 to 500 times more likely to be supported by existing literature than lower-ranking ones."
Dhindsa emphasized the role of these models as analytical tools that can validate emerging genes from sequencing studies. "We hope that our models will accelerate gene discovery and patient diagnoses," he added. Future studies aim to assess this possibility further.
This groundbreaking work involved multiple contributors, including Blake A. Weido, Justin S. Dhindsa, and Anthony W. Zoghbi, among others. Their affiliations include the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, AstraZeneca, and the University of Melbourne.
The research received financial support from various grants, including those from the NIH and Hevolution Foundation. As AI continues to evolve, its applications in genetic research may lead to new pathways for understanding and treating complex neurodevelopmental disorders.
Continue Your Tech Journey
Dive deeper into the world of Cryptocurrency and its impact on global finance.
Discover archived knowledge and digital history on the Internet Archive.
SciV1
